Shots:

• Health Canada has granted a NOC based on the P-II ZUMA-2 trial that evaluates Tecartus in 74 adult patients with r/r MCL who had previously received anthracycline or bendamustine containing CT, an anti-CD20 Ab therapy & BTK inhibitor
• The results demonstrated an ORR of 91%; patients achieving a CR (65%) as assessed by an independent radiologic review committee following a single infusion of Tecartus
• Tecartus is the 1st CAR T therapy to treat a patient with MCL after two or more lines of systemic therapy including BTK inhibitor. Additionally, kite becomes the first company with multiple authorized cell therapies in Canada

 ­to­  | Ref: Newswire.Ca | Image: Glassdoor